263 related articles for article (PubMed ID: 15517230)
1. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.
Morgia G; Falsaperla M; Malaponte G; Madonia M; Indelicato M; Travali S; Mazzarino MC
Urol Res; 2005 Feb; 33(1):44-50. PubMed ID: 15517230
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer.
Jung K; Nowak L; Lein M; Priem F; Schnorr D; Loening SA
Int J Cancer; 1997 Apr; 74(2):220-3. PubMed ID: 9133459
[TBL] [Abstract][Full Text] [Related]
3. Activities and polymorphisms of MMP-2 and MMP-9, smoking, diabetes and risk of prostate cancer.
Kiani A; Kamankesh M; Vaisi-Raygani A; Moradi MR; Tanhapour M; Rahimi Z; Elahi-Rad S; Bahrehmand F; Aliyari M; Aghaz F; Mozafari H; Rezvani N; Haghnazari L; Pourmotabbed T
Mol Biol Rep; 2020 Dec; 47(12):9373-9383. PubMed ID: 33165815
[TBL] [Abstract][Full Text] [Related]
4. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
5. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
Horstmann S; Kalb P; Koziol J; Gardner H; Wagner S
Stroke; 2003 Sep; 34(9):2165-70. PubMed ID: 12907822
[TBL] [Abstract][Full Text] [Related]
6. [Matrix metalloproteinases and their inhibitors in ovarian cancer progression--diagnostic and therapeutic implications].
Stettner R; Bogusiewicz M; Rechberger T
Ginekol Pol; 2009 Jan; 80(1):47-53. PubMed ID: 19323060
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer.
Kanoh Y; Akahoshi T; Ohara T; Ohtani N; Mashiko T; Ohtani S; Egawa S; Baba S
Anticancer Res; 2002; 22(3):1813-7. PubMed ID: 12168874
[TBL] [Abstract][Full Text] [Related]
8. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
10. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer.
Kushlinskii NE; Gershtein ES; Ivannikov AA; Davydov MM; Chang VL; Ognerubov NA; Stilidi IS
Bull Exp Biol Med; 2019 Jan; 166(3):373-376. PubMed ID: 30627896
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
14. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
Lorenzl S; Buerger K; Hampel H; Beal MF
Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
[TBL] [Abstract][Full Text] [Related]
15. The matrix metalloproteinase-7 and pro-enzyme of metalloproteinase-1 as a potential marker for patients with rectal cancer without distant metastasis.
Fuksiewicz M; Kotowicz B; Rutkowski A; Kowalska M
Tumour Biol; 2015 May; 36(5):3629-35. PubMed ID: 25549795
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
17. Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer.
De Cicco C; Ravasi L; Zorzino L; Sandri MT; Botteri E; Verweij F; Granchi D; de Cobelli O; Paganelli G
Curr Cancer Drug Targets; 2008 May; 8(3):199-206. PubMed ID: 18473733
[TBL] [Abstract][Full Text] [Related]
18. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients.
Giannelli G; Erriquez R; Fransvea E; Daniele A; Trerotoli P; Schittulli F; Grano M; Quaranta M; Antonaci S
Int J Cancer; 2004 May; 109(5):782-5. PubMed ID: 14999790
[TBL] [Abstract][Full Text] [Related]
19. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
20. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]